...been determined. Coherus takes territorial rights to Innovent’s Avastin biosimilar Innovent Biologics Inc. (HKSE:1801) granted Coherus BioSciences...
...subcutaneous semaglutide (Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent Biologics Inc. Coherus BioSciences...

...as its first chief commercial officer. Hassard was SVP of marketing and market access at Coherus BioSciences...

...pegfilgrastim launched in the U.S. in July 2018, it has been joined by Udenyca from Coherus Biosciences...
...value certainty in supply and patient and provider services.” The launch of Ziextenzo, the Sandoz biosimilar pegfilgrastim...
...CenTNF (Former), Avakine (Former), infliximab (Generic), Remicade (Other) Novartis AG Amgen Inc. Samsung Bioepis Co. Ltd. Mylan N.V. Sandoz IQVia Holdings Inc. Coherus BioSciences...

...sales in 3Q19, with a 31% decline in the U.S. FDA approved Udenyca pegfilgrastim-cbqv from Coherus Biosciences...
...$120 million. Mylan did not break out sales of its biosimilar. Steve Usdin, Washington Editor Sandoz Ltd. Amgen Inc. Coherus BioSciences...

...in the paper laying out the CSL proposal, he said. Forum members include Boehringer Ingelheim, Coherus BioSciences...
...LLC, Washington, DC BioApprovals, Acton, Mass. Biosimilars Forum, Washington, DC Boehringer Ingelheim GmbH, Ingelheim, Germany Coherus Biosciences...
...Israel U.S. Food and Drug Administration (FDA), Silver Spring, Md. Steve Usdin, Washington Editor Amgen Inc. Boehringer Ingelheim GmbH Coherus BioSciences...

...initial BLA in June 2016. Sandoz did not disclose what issues the agency raised (see "Biosimilar Pegfilgrastim...

...of business development at Denali Therapeutics Inc. (NASDAQ:DNLI), and Robbins was VP of IP at Coherus BioSciences...

...the company is not contemplating any additional deals "of that magnitude." Also on Jan. 25, Coherus BioSciences...

...Inc., the company is not contemplating any additional deals "of that magnitude." Also on Friday, Coherus BioSciences...

...Roche (SIX:ROG; OTCQX:RHHBY) China’s National Medical Products Administration approves Hemlibra emicizumab to treat hemophilia A Coherus Biosciences...